Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Despite the promising result with FLT3 inhibitors in AML, the emergence of resistance poses a significant challenge, leading to a shorter response duration and inferior survival. This is frequently driven by on-target or parallel prosurvival mutations. The emergence of BCR–ABL1 as a mechanism of pos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Alotaibi, Ahmad S., Yilmaz, Musa, Loghavi, Sanam, DiNardo, Courtney, Borthakur, Gautam, Kadia, Tapan M., Thakral, Beenu, Pemmaraju, Naveen, Issa, Ghayas C., Konopleva, Marina, Short, Nicholas J., Patel, Keyur, Tang, Guilin, Ravandi, Farhad, Daver, Naval
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606916/
https://ncbi.nlm.nih.gov/pubmed/33194747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.588876
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados